Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Retained Earnings (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Retained Earnings for 5 consecutive years, with $125000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 43.18% to $125000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $125000.0 through Dec 2025, down 43.18% year-over-year, with the annual reading at $125000.0 for FY2025, 43.18% down from the prior year.
  • Retained Earnings hit $125000.0 in Q4 2025 for ARS Pharmaceuticals, up from -$7000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $339000.0 in Q3 2024 to a low of -$230.3 million in Q2 2022.
  • Historically, Retained Earnings has averaged -$51.5 million across 5 years, with a median of -$180000.0 in 2023.
  • Biggest five-year swings in Retained Earnings: soared 348.98% in 2024 and later crashed 126710.48% in 2025.
  • Year by year, Retained Earnings stood at -$162.8 million in 2021, then surged by 52.73% to -$76.9 million in 2022, then skyrocketed by 100.06% to $49000.0 in 2023, then soared by 348.98% to $220000.0 in 2024, then crashed by 43.18% to $125000.0 in 2025.
  • Business Quant data shows Retained Earnings for SPRY at $125000.0 in Q4 2025, -$7000.0 in Q3 2025, and -$46000.0 in Q2 2025.